HUTCHMED (China) Limited
HMDCF
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.48B
Close$
Share Statistics
| Market cap | $2.48 Billion |
|---|---|
| Enterprise Value | $2.47 Billion |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | 1.42% |
|---|---|
| Return on Assets | 1.03% |
| Return on Invested Capital | -2.38% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 4.49 |
| Enterprise Value to EBIT | -70.89 |
| Enterprise Value to Net Income | 137 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
$0.03
Average shareholder expectationRevenue Estimate
$304.16 M
Average shareholder expectationNext Earnings Call
Expected Date
March 4, 2027
EPS Estimate
$0.04
Average shareholder expectationRevenue Estimate
$329.08 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Hutchison China Meditech Ltd.
1,796 employees
CEO: Christian Hogg HUTCHMED (China) Limited, a biopharmaceutical company established in 2000 and headquartered in Central, Hong Kong, focuses on the discovery, development, and commercialization of innovative targeted therapies and immunotherapies. The com...